The authors evaluated whether tumour markers can be considered useful in prognosis and therapeutical planning of renal cell carcinoma. This review has focused on those cytochemical and laboratory markers which are not only related to prognosis, but also give more information on therapeutical planning, particularly with regard to immuno and chemotherapy.
MiserezA.R., Muller-BrandJ., RistM., MackeH.: Clinical value of a mucin-like carcinoma-associated antigen (MCA) in patients with carcinomas of the kidney and urinary collecting system. Int. J. Biol. Markers, 6 (1): 7–11, 1991.
3.
MoliardM., BoazizC., RaymondE., MorereJ.F., BreauJ.L., IsraelL.: Distribution of tumour markers in renal cancer. Ecco, 6: 566, 1991.
4.
BassettoM.A., FranceschiT., ZaninelliM., LenottiM., PancheriF., SchinellaM., CettoG.L.: Evaluation of MCA serum levels in patients with metastatic renal cell carcinoma. Proc. Annu. Meet. Soc. Clini. Oncol., 9: 546, 1990.
5.
De RieseW., CrabtreeW.N., AllhoffE.P., WernerM., LiedkeS., LenisG., AtzpodienJ., KirchnerH.: Prognostic significance of Ki-67 immunostaining in non metastatic renal cell carcinoma. Journal of Clinical Oncology, 11 (9): 1804–1808, 1993.
6.
HannisdalE., BostadiL., GrottumK.A., LangmarkF.: Erythrocyte sedimentation rate as a prognostic factor in renal cell carcinoma. E. Journal of Surgical Oncology, 15: 333–336, 1989.
7.
RasmusonT., GrankvistK., LjungbergB.: Serum gammaenolase and prognosis of patients with renal cell carcinoma. Cancer, August 15, 72 (4): 1324–1328, 1993.
8.
RasmusonT., GrankvistK., LjungbergB.: Serum beta-2-microglobulin and prognosis in renal cell carcinoma. Asco, 12 (252): 797, 1993.
9.
RasmusonT., BjörkG.R., HietalaS.O., StenlingR., LjungbergB.: Excretion of pseudouridine as an independent prognostic factor in renal cell carcinoma. Acta Oncologica, 30 (1): 11–15, 1991.
10.
EpelbaumR., MoskovitzB., SegaiR., MekoriT., NativO., ShalitinC.: The significance of a 21kDa protein serum levels in the follow-up of patients with renal cell carcinoma after radicai nephrectomy. Ecco, 7: 1305, 1992.
11.
DosquetC., SchaetzA., FaucherC., LepageE., WautierJ.L., RichardF., CabaneJ.: TNF, IL1b and IL6 in patients with renal cell carcinoma. E. Journal of Cancer, 30A (2): 162–167, 1994.
12.
BlayJ.Y., NegrierS., CombaretV., GoillotE., MercatelloA., RavaudA., TouraniJ.M., MoskovtchenkoJ.F., PhilipT., FavrotM.: IL6 and metastatic clear cell renal carcinoma: a prognosis factor for response and survival after IL2 therapy. Asco, 11 (217): 684, 1992.
13.
NanusD.M., PfefferL.M., BanderN.H.: Antiproliferative and antitumour effects of alpha-interferon in renal cell carcinomas: correlation with the expression of kidney-associated differentiation glycoprotein. Cancer Res., 50: 4190–4194, 1990.
14.
JanikJ.E., SznolM., UrbaW., FiglinR., BukowskiR.M., FyfeG., PierceW., BelldegrunA., SharfmanW.H1, SmithJ.W., LongoD.: Erythropoietin production. A potential marker of IL2/IFN responsive tumours. Cancer November 1, 72: 9, 1993.
